Amgen (AMGN) has been performing strongly in the market, offering a solid dividend policy. The company has been recognised for its performance as it surpasses market returns. The US FDA has approved
Amgen's Uplizna as the first treatment for a rare immune disorder, and this has played a significant role in Amgen's recent successes. The drug's approval for treating IgG4-Related Disease has increased Amgen's stock position among financial firms, including one ascent Financial Services LLC, Pitcairn, and Motley Fool Asset Management LLC. The
Q4 earnings of Amgen outperformed other therapeutics stocks. One notable transaction is that Allstate Corp invested $4.16 million into the company while the financial group Alliancebernstein L.P. sold a significant number of shares. Approval of Uplizna for chronic immune-mediated fibroinflammatory disorder has also added value to the company, positioning it as a top pick for both long term and dividend investing. The
Q4 earnings along with full year 2024 financial results and projected dividends for 2025 second quarter indicate a profitable future for investors.
Amgen AMGN News Analytics from Tue, 26 Nov 2024 08:00:00 GMT to Sat, 05 Apr 2025 13:01:06 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 3
